Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria
- PMID: 19506065
- PMCID: PMC2715578
- DOI: 10.1128/AAC.00418-09
Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria
Abstract
The antibacterial spectrum of besifloxacin, a novel fluoroquinolone recently approved for treatment of ocular infections, was studied using 2,690 clinical isolates representing 40 species. Overall, besifloxacin was the most potent agent tested against gram-positive pathogens and anaerobes and was generally equivalent to comparator fluoroquinolones in activity against most gram-negative pathogens. Besifloxacin demonstrated potent, broad-spectrum activity, which was particularly notable against gram-positive and gram-negative isolates that were resistant to other fluoroquinolones and classes of antibacterial agents.
Figures
References
-
- American Academy of Ophthalmology. Conjunctivitis, preferred practice pattern. 2003. American Academy of Ophthalmology, San Francisco, CA.
-
- Asbell, P. A., K. A. Colby, S. Deng, P. McDonnell, D. M. Meisler, M. B. Raizman, J. D. Sheppard, Jr., and D. F. Sahm. 2008. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am. J. Ophthalmol. 145:951-958. - PubMed
-
- Blondeau, J. M., L. Brunner, and S. Norton. 2006. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-2001.
-
- Blondeau, J. M., L. Brunner, and S. Norton. 2006. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-2002.
-
- Brunner, L., S. Norton, and J. M. Blondeau. 2007. Abstr. 17th Eur. Congr. Clin. Microbiol. Infect. Dis., abstr. P1679.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
